Also known as: Ang(1-7) · Angiotensin-(1-7)
Angiotensin 1-7 is an endogenous heptapeptide of the renin-angiotensin system (RAS), produced primarily by ACE2 cleavage of Angiotensin II. It acts as the physiological counter-regulator to Angiotensin II, producing vasodilation, anti-fibrosis, anti-inflammation, and cardioprotection through the Mas receptor.
Angiotensin 1-7 represents the protective arm of the renin-angiotensin system (RAS), opposing the vasoconstriction, inflammation, and fibrosis driven by Angiotensin II (Ang II) through the AT1R receptor. The balance between the ACE/Ang II/AT1R axis and the ACE2/Ang(1-7)/MasR axis determines cardiovascular and renal homeostasis.
Interest in Ang(1-7) surged during the COVID-19 pandemic, as SARS-CoV-2 uses ACE2 as its cellular entry receptor — effectively depleting ACE2 activity and shifting the RAS balance toward pro-inflammatory Ang II signaling. Ang(1-7) deficiency may contribute to COVID-19-associated cardiovascular complications, driving trials of exogenous Ang(1-7) therapy.
Ang(1-7) binds the G-protein-coupled Mas receptor (MasR), triggering eNOS (endothelial nitric oxide synthase) activation and subsequent NO production, causing vasodilation. MasR signaling also inhibits NADPH oxidase, reducing oxidative stress in vascular endothelium.
By opposing Ang II-mediated TGF-β1 signaling, Ang(1-7) reduces myofibroblast activation and collagen deposition in cardiac and renal tissue. This anti-fibrotic effect has therapeutic potential in heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy.
Ask anything about Angiotensin 1-7 — mechanisms, dosing protocols, interactions, or research comparisons.